calcium acetate · Fresenius Medcl Care · NDA 022581
Phoslyra
Earliest generic entry, as listed
23 Feb 2030
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8591938.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8591938 | drug product, use U-1469 · sets the listed date | 23 Feb 2030 |
| US 8592480 | use U-1469 | 20 Jul 2027 |
| US 9089528 | use U-1469 | 20 Jul 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022581 · 001 · RLD · discontinued | solution, oral | 667MG/5ML | 23 Feb 2030 |